Life Science Pharmacy Recalls BI-EST Lozenges Due to Penicillin Contamination
Life Science Pharmacy Inc. is recalling BI-EST Lozenges because they may be contaminated with penicillin. The recall covers all lots distributed nationwide.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II, and the rubric specifies that FDA Class II recalls with potential for significant injury (such as penicillin contamination) are rated as Severe.
Plain-English summary
Life Science Pharmacy Inc. is recalling BI-EST Lozenges, a prescription compounded product, due to potential cross-contamination with penicillin. The recall includes all lots of the product.
The product was distributed nationwide. The source text does not specify the number of units affected or the specific dates of distribution.
Consumers who have this product should stop using it and contact their healthcare provider or pharmacist for further instructions.
The recalled product
- Product
- BI-EST Lozenges, Rx, compounded by Life Science Pharmacy Inc., Harriman, NY
- Manufacturer
- Life Science Pharmacy Inc
- Category
- Drug — Compounded Prescription
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 23 recalled by Life Science Pharmacy Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 23 products in this recall →Related recalls
Same manufacturer · Life Science Pharmacy Inc
See all →- SevereLife Science Pharmacy Recalls TRI-EST Lozenges Due to Penicillin Contamination
FDA (Drugs) · 2015-12-09
- SevereLife Science Pharmacy Recalls HCG Injections Due to Penicillin Contamination
FDA (Drugs) · 2015-12-09
- HighLife Science Pharmacy Recalls Compounded Estriol Vaginal Creams
FDA (Drugs) · 2015-12-09
- SevereLife Science Pharmacy Recalls Compounded Estriol Creams Due to Penicillin Contamination
FDA (Drugs) · 2015-12-09
- SevereLife Science Pharmacy Recalls BI-EST Capsules Due to Penicillin Contamination
FDA (Drugs) · 2015-12-09
Same hazard · penicillin contamination
See all →- SevereGlaxoSmithKline Recalls Bactroban Nasal Ointment Due to Penicillin Contamination
FDA (Drugs) · 2016-07-27
- SevereGlaxoSmithKline Recalls Bactroban Cream Due to Penicillin Cross Contamination
FDA (Drugs) · 2016-07-27
- SevereGlaxoSmithKline Recalls Bactroban Cream Due to Penicillin Cross Contamination
FDA (Drugs) · 2016-07-27
- SevereLife Science Pharmacy Recalls TRI-EST Liquids Due to Penicillin Contamination
FDA (Drugs) · 2015-12-09
Similar recalls
- HighAttix Pharmaceuticals Recalls Exemestane API Due to Penicillin Cross-Contamination Risk
FDA (Drugs) · 2015-04-29
- SevereBi-Est 80:20 Progesterone Capsules Recalled for Penicillin Cross Contamination
FDA (Drugs) · 2015-09-09
- SevereThe Compounder Recalls BIEST CP 80/20 Capsules Due to Penicillin Contamination
FDA (Drugs) · 2015-11-18
- SevereAttix Pharmaceuticals Recalls Cetirizine HCI Due to Penicillin Cross-Contamination Risk
FDA (Drugs) · 2015-04-29
- SevereBi-Est Cream Recalled for Potential Penicillin Cross Contamination
FDA (Drugs) · 2015-09-09
- SevereThe Compounder Recalls BIEST TD 80/20 Transdermal Cream Due to Penicillin Contamination
FDA (Drugs) · 2015-11-18